Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMPART: Radiotherapy and Cemiplimab for Locally Advanced CSCC
NCT05574101Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2022
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2022; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05574101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574101.